Shares of health-care companies rose on deal activity.
Sanofi agreed to buy Belgian biotech Ablynx for $4.85 billion, the French drugmaker's second acquisition this month after purchasing U.S. hemophilia specialist Bioverativ.
Continue Reading Below
Other large-cap drug makers, including Celgene, have also made acquisitions of midsize drug developers in the latest scramble to bolster drug pipelines.
Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
January 29, 2018 17:39 ET (22:39 GMT)